Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab for recurrent/refractory peripheral T‑cell lymphoma (W-JHS NHL02)
jRCT2071210101Phase 2Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL) and 4 more, sponsored by Ono Pharmaceutical. Primary endpoint: Overall response rate (ORR). Started Apr 2019; status: active, not recruiting.
02
Drugs
03
Conditions
peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)anaplastic large cell lymphoma (ALCL)enteropathy-associated T-cell lymphoma (EATL)hepatosplenic T-cell lymphoma (HSTCL)
Beyond the preview
Go deeper on jRCT2071210101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210101.